Allogene Therapeutics ALLO Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's free cash flow?
- Allogene Therapeutics (ALLO) reported free cash flow of -$12.92M in Q1 2026.
- How has Allogene Therapeutics's free cash flow changed year-over-year?
- Allogene Therapeutics's free cash flow increased by 75.6% year-over-year, from -$53.03M to -$12.92M.
- What is the long-term trend for Allogene Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Allogene Therapeutics's free cash flow has grown at a -7.7% compound annual growth rate (CAGR), from -$206.26M to -$149.63M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.